Alan P. Skarbnik, MD, Novant Health Cancer Institute
Advertisement
Articles by Alan P. Skarbnik, MD, Novant Health Cancer Institute
Advertisement
Latest Updated Articles
Therapeutic Sequencing in Relapsed/Refractory CLLJanuary 8th 2021
Allogeneic Transplantation for CLLJanuary 8th 2021
Frontline CLL Treatment: Addressing Unmet NeedsJanuary 8th 2021
Selecting Frontline Therapy to Treat CLLJanuary 8th 2021
Frontline CLL Treatment With Fixed-Duration RegimensJanuary 8th 2021
Minimal Residual Disease in CLLJanuary 8th 2021
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
3
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5